11.13.13
KGK Synergize Inc., a London, Ontario-based contract research organization (CRO) offering human clinical trials to the health nutrition industry, has entered into a non-binding letter of intent with the Center for Applied Health Sciences (CAHS), Stow, OH. CAHS is CRO catering to the natural health products/dietary supplement industry with a special focus on human performance and sports nutrition. Pending satisfactory completion of due diligence, KGK Synergize will enter into a definitive partnership agreement with CAHS. The final announcement outlining the structure of KGK's acquisition and details of the agreement is expected to be finalized before the end of the year.
“This partnership is very exciting for KGK as it allows us instant access into the U.S. market,” stated Najla Guthrie, president and CEO of KGK Synergize Inc. “The partnership will also open up the door for us to have strong presence in the sports nutrition industry. We are looking forward to the senior management team and executives at CAHS playing a key role in the growth and success of KGK Synergize U.S. Inc.”
“KGK has established themselves as a leading CRO and our team is excited about the possibility to help grow both the KGK and CAHS brands,” said Tim Ziegenfuss, PhD, CSCS, FISSN, founder and CEO of CAHS. “Their expertise in clinical trial design, project management, and rapid publication of data will help us streamline our services for current and future CAHS clients. Ultimately, this partnership will help establish KGK and CAHS as worldwide leaders in human clinical trial research.”
“This partnership is very exciting for KGK as it allows us instant access into the U.S. market,” stated Najla Guthrie, president and CEO of KGK Synergize Inc. “The partnership will also open up the door for us to have strong presence in the sports nutrition industry. We are looking forward to the senior management team and executives at CAHS playing a key role in the growth and success of KGK Synergize U.S. Inc.”
“KGK has established themselves as a leading CRO and our team is excited about the possibility to help grow both the KGK and CAHS brands,” said Tim Ziegenfuss, PhD, CSCS, FISSN, founder and CEO of CAHS. “Their expertise in clinical trial design, project management, and rapid publication of data will help us streamline our services for current and future CAHS clients. Ultimately, this partnership will help establish KGK and CAHS as worldwide leaders in human clinical trial research.”
